Meeting Report

2017-2018 Drug Approvals in Solid Tumors

Presented by Patrick J. Kiel, PharmD, BCPS, BCOP

Indiana University Simon Cancer Center, Indianapolis, Indiana

Presenter’s disclosures of conflicts of interest are found at the end of this article.


J Adv Pract Oncol 2019;10(3):218–224 | https://doi.org/10.6004/jadpro.2019.10.3.3 | © 2019 Harborside™


  

ABSTRACT

New oncology approvals from 2017 to 2018 were mostly for additional indications, with many agents moved up to first-line therapy. Patrick J. Kiel, PharmD, BCPS, BCOP, detailed their implications for advanced practice.




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.